142 related articles for article (PubMed ID: 2337903)
1. Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markers.
Maghazachi AA; Fitzgibbon L
Cancer Immunol Immunother; 1990; 31(3):139-45. PubMed ID: 2337903
[TBL] [Abstract][Full Text] [Related]
2. Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels.
Wiltrout RH; Gorelik E; Brunda MJ; Holden HT; Herberman RB
Cancer Immunol Immunother; 1983; 14(3):172-9. PubMed ID: 6404550
[TBL] [Abstract][Full Text] [Related]
3. Influence of T cells on the expression of lymphokine-activated killer cell activity and in vivo tissue distribution.
Maghazachi AA; Goldfarb RH; Herberman RB
J Immunol; 1988 Dec; 141(11):4039-46. PubMed ID: 2846699
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
5. In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells.
Maghazachi AA; Herberman RB; Vujanovic NL; Hiserodt JC
Cell Immunol; 1988 Aug; 115(1):179-94. PubMed ID: 3261203
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels.
Basse P; Herberman RB; Hokland M; Goldfarb RH
Cancer Immunol Immunother; 1992; 34(4):221-7. PubMed ID: 1537054
[TBL] [Abstract][Full Text] [Related]
7. The in vivo distribution of murine lymphokine activated killer cells in splenectomized host.
Chao TY; Chu TM
Proc Natl Sci Counc Repub China B; 1990 Dec; 14(4):223-7. PubMed ID: 2101449
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion.
Kuppen PJ; Marinelli A; Camps JA; Pauwels EK; van de Velde CJ; Fleuren GJ; Eggermont AM
Int J Cancer; 1992 Sep; 52(2):266-70. PubMed ID: 1521913
[TBL] [Abstract][Full Text] [Related]
9. In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells.
Futami H; Pilaro AM; Gruys ME; Back TC; Young HA; Wiltrout RH
Biotherapy; 1991; 3(3):219-32. PubMed ID: 1906724
[TBL] [Abstract][Full Text] [Related]
10. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.
Felgar RE; Hiserodt JC
Cell Immunol; 1990 Sep; 129(2):288-98. PubMed ID: 2383892
[TBL] [Abstract][Full Text] [Related]
11. Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration.
Basse PH; Herberman RB; Hokland ME; Goldfarb RH
Nat Immun; 1992; 11(4):193-202. PubMed ID: 1421955
[TBL] [Abstract][Full Text] [Related]
12. Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma.
Schäfer E; Dummer R; Eilles C; Börner W; Martin R; Rendl J; Burg G
Eur J Nucl Med; 1991; 18(2):106-10. PubMed ID: 2044569
[TBL] [Abstract][Full Text] [Related]
13. Effect of tumor irradiation on the uptake of lymphokine-activated killer cells in a murine tumor model.
Munshi NC; Williams JR
Cancer Res; 1994 Apr; 54(7):1657-9. PubMed ID: 8137277
[TBL] [Abstract][Full Text] [Related]
14. Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin.
Kuppen PJ; Eggermont AM; Marinelli A; de Heer E; van de Velde CJ; Fleuren GJ
Cancer Immunol Immunother; 1991; 33(1):28-32. PubMed ID: 2021956
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
16. Liver sequestration of murine lymphokine activated killer (LAK) cells is mediated by carbohydrate-specific receptors.
Samlowski WE; McGregor JR; Litton GJ
Reg Immunol; 1989; 2(4):254-65. PubMed ID: 2484335
[TBL] [Abstract][Full Text] [Related]
17. [In vivo distributions of 111In and/or 3H labeled lymphocyte in C3H/He mouse (author's transl)].
Shibata C; Shiwaku Y; Ohizumi Y; Maezawa H; Okumura Y; Suzuki Y; Tsuji K; Mori T
Radioisotopes; 1979 Jul; 28(7):431-6. PubMed ID: 504725
[TBL] [Abstract][Full Text] [Related]
18. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
19. Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation, or splenectomy.
Kawata A; Hosokawa M; Sawamura Y; Ito K; Une Y; Shibata T; Uchino J; Kobayashi H
Mol Biother; 1990 Dec; 2(4):221-7. PubMed ID: 2288722
[TBL] [Abstract][Full Text] [Related]
20. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
Lefor AT; Rosenberg SA
J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
